Hepatorenal syndrome is a form of kidney failure that develops not because the kidneys themselves are damaged, but because severe liver disease starves them of blood flow. It occurs almost exclusively in people with advanced cirrhosis or acute liver failure, and without treatment it can be fatal within weeks. The kidneys are structurally intact, which is what makes the condition so distinctive and, in theory, reversible if the liver problem can be corrected. Understanding what drives it, how it is recognized, and what treatments exist is critical because the window for intervention is narrow and the stakes are high.
How Liver Disease Causes Kidney Failure
The mechanism behind hepatorenal syndrome starts in the blood vessels surrounding the gut. As cirrhosis worsens, rising pressure in the portal vein (the main vessel feeding the liver) causes the blood vessels in the abdominal organs to widen dramatically. This widening pulls blood into the belly’s circulation, reducing the volume of blood effectively available to the rest of the body. The body interprets this as low blood pressure, even though total blood volume may be normal or even high.
To compensate, the body activates powerful stress-response systems that constrict blood vessels elsewhere, retain salt and water, and try to prop up blood pressure. The kidneys bear the brunt of this response. Blood flow to the kidneys drops sharply, the filtration rate plummets, and urine output falls. Because the kidney tissue itself is not scarred or inflamed, the damage is classified as “functional” rather than structural. If you were to transplant those kidneys into a healthy person, they would work fine.
This cascade of splanchnic vasodilation, reduced effective blood volume, and intense renal vasoconstriction has been understood for decades and remains the core explanation for the syndrome.1PubMed Central. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options More recently, researchers have recognized that systemic inflammation, which is common in advanced cirrhosis, also plays a significant role in driving kidney injury on top of the circulatory problem.2PubMed Central. Hepatorenal Syndrome
The Role of the Heart
The traditional explanation focuses on blood vessels in the abdomen, but there is a cardiac piece that often goes underappreciated. Advanced cirrhosis can weaken the heart muscle itself, a condition sometimes called cirrhotic cardiomyopathy. When cardiac output drops, the kidneys lose even more perfusion. A study measuring cardiac index in cirrhotic patients with ascites found that those with a cardiac index below 1.5 liters per minute per square meter had dramatically lower kidney blood flow and higher creatinine levels. Among patients in the low-output group, over 40% developed hepatorenal syndrome within three months, compared with only 5% in the higher-output group.3Gut. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites This suggests that in some patients, a failing heart is the tipping point that pushes kidneys over the edge, not just the vascular dilation alone.4PubMed Central. Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review
What Triggers an Episode
Hepatorenal syndrome rarely appears out of nowhere. It usually follows a recognizable trigger in someone whose liver is already in bad shape. The most common precipitant is a bacterial infection, especially spontaneous bacterial peritonitis (SBP), an infection of the fluid that accumulates in the abdomen. Gastrointestinal bleeding, aggressive use of diuretics, and large-volume paracentesis (draining abdominal fluid) without adequate albumin replacement can all push a fragile system into kidney failure.
One surprising finding involves beta-blockers, which are commonly prescribed to prevent variceal bleeding in cirrhosis. A study of patients with cirrhosis and SBP found that those taking nonselective beta-blockers developed hepatorenal syndrome at roughly twice the rate of those not on the drugs (24% versus 11%).5PubMed. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis This does not mean beta-blockers are always harmful in cirrhosis, but it highlights the delicate balance involved: medications that help in one context can become dangerous in another.
Preventing the Syndrome Before It Starts
The single best-studied preventive strategy is giving intravenous albumin alongside antibiotics when a patient with cirrhosis develops spontaneous bacterial peritonitis. A landmark trial found that adding albumin to standard antibiotic therapy cut the rate of kidney impairment from about a third of patients down to 10%, and reduced in-hospital mortality from 29% to 10%.6PubMed. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis This has become standard practice in hospitals managing decompensated cirrhosis. The logic fits the pathophysiology: albumin expands effective blood volume, counteracting the underfilling that drives kidney vasoconstriction. Early identification and treatment of infections more broadly is considered a key prevention measure.7Nature Reviews Disease Primers. Hepatorenal syndrome
How Hepatorenal Syndrome Is Diagnosed
Diagnosing hepatorenal syndrome is fundamentally a process of ruling out other explanations for kidney failure. There is no single blood test that confirms it. Clinicians look for worsening kidney function in a patient with advanced liver disease who is not responding to fluid resuscitation with albumin, has no evidence of shock, has not recently used kidney-toxic drugs, and does not have structural kidney disease on imaging. The kidneys look normal on ultrasound, which is part of the diagnostic puzzle: they appear healthy but are not working.
The classification system has evolved over the years. The older framework divided the syndrome into type 1 (a rapid, severe deterioration in kidney function, often doubling creatinine within two weeks) and type 2 (a slower, more stable decline typically linked to stubborn ascites). More recently, the International Club of Ascites updated the terminology to align with broader acute kidney injury staging, referring to the acute form as HRS-AKI. The underlying idea has not changed much, but the newer criteria allow earlier recognition and faster initiation of treatment.
Emerging Biomarkers
Researchers have been hunting for urine or blood markers that could distinguish hepatorenal syndrome from other types of kidney injury in cirrhotic patients earlier and more reliably. Two markers that keep appearing in studies are urinary KIM-1 (kidney injury molecule-1) and urinary NGAL (neutrophil gelatinase-associated lipocalin). Both reflect kidney tubular stress, and both have shown promising ability to predict which cirrhotic patients will develop kidney failure.
In one study of advanced cirrhotic patients, urinary NGAL and KIM-1 at baseline were each significantly associated with later development of hepatorenal syndrome, with area-under-the-curve values of 0.84 and 0.78 respectively.8PubMed. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis Another study found that combining urinary KIM-1, urinary NGAL, and serum cystatin C together yielded even better predictive accuracy, with sensitivity of 87% and specificity of nearly 96%.9Scientific Reports. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis These are not yet part of routine clinical practice, but they represent the direction the field is moving: toward catching kidney trouble before creatinine has already spiked, when intervention stands a better chance of working.
Drug Treatment Options
The first-line medical approach to hepatorenal syndrome involves pairing a vasoconstrictor drug with intravenous albumin. The vasoconstrictor tightens up the dilated blood vessels in the abdomen, redirecting blood flow back to the kidneys, while albumin expands the circulating volume. Three vasoconstrictor strategies are in use, and they are not equally effective.
Terlipressin
Terlipressin, a synthetic vasopressin analogue, has the strongest evidence base. In the CONFIRM trial, the largest randomized trial of terlipressin for the syndrome, about 32% of patients on terlipressin achieved verified reversal of kidney failure compared with 17% on placebo. Among patients who also had signs of systemic inflammation, the difference was even more stark: 37% reversed on terlipressin versus just 6% on placebo.10PubMed. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome An earlier randomized trial also showed terlipressin plus albumin reversing kidney function in roughly 44% of patients versus about 9% on albumin alone.11Gastroenterology. Terlipressin and Albumin Combined in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized, Controlled Trial
One important caveat with terlipressin: relapse rates differ depending on the form of the syndrome. A study comparing outcomes in patients with the rapid-onset and slower forms found that while initial reversal rates were similar (around 47-48%), patients with the slower form relapsed at a much higher rate, 50% compared with 8% in those with the acute form.12PubMed Central. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2 This makes sense: the chronic form persists because the underlying liver disease is still generating the circulatory problem, so the kidneys tend to fail again once the drug is stopped.
Norepinephrine and Midodrine Plus Octreotide
Norepinephrine (noradrenaline) is the main alternative vasoconstrictor. It requires an intensive care setting for administration since it is given as a continuous intravenous drip. A randomized trial comparing norepinephrine to midodrine-plus-octreotide (the oral/subcutaneous alternative sometimes used outside the ICU) found full response rates of about 58% with norepinephrine versus 20% with midodrine-octreotide.13PubMed Central. Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial A systematic review and network meta-analysis confirmed that both terlipressin and norepinephrine are substantially better at reversing hepatorenal syndrome than midodrine-octreotide.14The Lancet Gastroenterology & Hepatology. Comparative efficacy of management strategies in type 1 hepatorenal syndrome: a systematic review and network meta-analysis
That said, one smaller trial found comparable reversal rates between norepinephrine and midodrine-octreotide (about 73% versus 75%), with no significant difference in three-month outcomes.15PubMed Central. Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial Studies in this area tend to be small, and results vary. The general consensus is that terlipressin or norepinephrine should be preferred when available, with midodrine-octreotide reserved for settings where neither can be used.
Safety Concerns with Terlipressin
Terlipressin’s approval in the United States in 2022 came with a prominent warning about respiratory side effects. In the CONFIRM trial, patients with the most severe liver failure (grade 3 acute-on-chronic liver failure) who received terlipressin developed respiratory failure at a rate of 30%, compared with 0% of grade 3 patients on placebo. Deaths attributed to respiratory failure within 30 days were also concentrated in this sickest subgroup: about 23% of grade 3 patients on terlipressin versus none on placebo.16PubMed Central. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
The mechanism likely involves fluid overload. Terlipressin shifts blood from the splanchnic circulation back into the central compartment. In a patient whose heart is already struggling and whose albumin levels are low, that extra volume can overwhelm the lungs. Clinical guidance now emphasizes careful fluid monitoring, avoiding terlipressin in patients with oxygen saturation issues or severe multi-organ failure, and being ready to stop the drug at the first sign of breathing difficulty.17PubMed Central. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance For patients with less severe liver failure, the respiratory risk appears much lower, and the benefit of kidney recovery generally outweighs the risk.
TIPS as a Bridge Procedure
Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure in which a radiologist creates a channel inside the liver connecting the portal vein to the hepatic vein. This decompresses the portal system directly, addressing one of the root causes of the circulatory mess. An early study of TIPS in patients with the acute form of the syndrome showed striking improvements: portal pressure dropped by half, and kidney function improved in six of seven patients, with creatinine falling from an average of 5 to 1.8 mg/dL within 30 days. The stress-hormone systems driving kidney vasoconstriction also quieted down significantly.18PubMed. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems
A meta-analysis pooling available studies found that renal function improved in about 93% of acute-form patients and 83% across all forms after TIPS placement.19PubMed. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis Those numbers are impressive, but TIPS is not suitable for everyone. Patients need enough residual liver function to tolerate the procedure, because it diverts blood away from liver tissue. In very advanced liver failure, TIPS can worsen hepatic encephalopathy or precipitate further liver deterioration. It is most useful as a bridge to transplant or in carefully selected patients who have not responded to vasoconstrictor therapy.
Liver Transplantation as Definitive Treatment
Because the kidneys in hepatorenal syndrome are functionally impaired rather than structurally destroyed, replacing the diseased liver corrects the underlying circulatory problem and allows the kidneys to recover. Liver transplantation remains the only definitive cure. Most patients who receive a transplant in time see their kidney function return, though some who have had prolonged or severe kidney injury before transplant may have lasting renal damage.
For patients whose kidneys have been failing long enough that recovery is uncertain, simultaneous liver-kidney transplantation (SLKT) is an option. Current guidelines generally consider SLKT when estimated kidney filtration has been very low for at least four to eight weeks, among other criteria.20PubMed Central. Outcomes of liver transplantation in patients with hepatorenal syndrome A single-center review found that patients who received both organs had better one-year and five-year survival (92% and 82%) compared with those who received a liver alone (73% and 64%).21Journal of the American College of Surgeons. Results of Simultaneous Liver and Kidney Transplantation: A Single-Center Review However, there is ongoing debate about whether SLKT truly offers long-term advantages over liver transplantation alone, since many livers-only recipients do regain adequate kidney function after the liver starts working.
Prognosis and What Determines Survival
Without treatment, the acute form of hepatorenal syndrome historically carried a median survival measured in weeks. Even with modern vasoconstrictor therapy, the prognosis depends heavily on how sick the liver is overall. An analysis of patients treated with terlipressin and albumin found that 90-day mortality was tied to patient age, white blood cell count (a proxy for inflammation), the grade of acute-on-chronic liver failure, and whether the patient responded to treatment. Failure to respond to therapy roughly doubled the hazard of death.22PubMed. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome
The blunt reality is that reversing kidney function with drugs buys time, but it does not fix the liver. Patients who respond to vasoconstrictors but do not receive a transplant remain at high risk for recurrence and death from progressive liver disease. The goal of medical treatment is to stabilize kidney function long enough to get the patient to transplant, or at least to a clinical state where transplant evaluation is possible.
Living with and After the Syndrome
Even patients who survive an episode of hepatorenal syndrome often face significant ongoing challenges. A recent study examining quality of life found that survivors reported moderate impairment in both physical and mental health. Fatigue was the most common complaint (73%), followed by fluid retention (53%) and shortness of breath (47%). Psychological distress was reported by 87% of patients, and over half expressed substantial fear of being rehospitalized.23PubMed Central. Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences When asked about future care preferences in case of deterioration, about half favored intensive treatment, 7% preferred a palliative approach, and 40% were undecided. These findings underscore how much the syndrome takes out of people beyond the acute hospitalization.
Hepatorenal Syndrome in Children
Though far less common in pediatric patients, hepatorenal syndrome does occur in children with cirrhosis or acute liver failure. Its incidence is estimated at around 5% in children with chronic liver conditions who are awaiting transplant.24PubMed Central. Hepatorenal syndrome in children: a review The pathophysiology mirrors the adult version: reduced effective blood volume, compensatory vasoconstriction, and functional kidney failure. Biliary atresia, the most common reason for liver transplant in children, can progress to the point where hepatorenal syndrome and other complications of advanced portal hypertension become relevant.25PubMed Central. Diagnostic and management guidelines for biliary atresia in 2025
Treatment in children follows the same principles as in adults: albumin expansion, vasoconstrictors (primarily terlipressin), and liver transplant as the ultimate goal. Dosing and monitoring are adapted for pediatric patients, but the evidence base is thin compared with adult data, and many treatment decisions rely on extrapolation from adult trials. Extracorporeal liver support devices sometimes serve as a bridge to transplant in children when drug therapy fails.
The Cost of Treatment
The financial side of managing hepatorenal syndrome is striking and relevant to both patients and the healthcare systems making formulary decisions. A U.S. hospital-perspective analysis found that the cost per complete response with terlipressin plus albumin was roughly $452,000, which was about half the cost per response with norepinephrine plus albumin (around $931,000), largely because norepinephrine requires expensive ICU-level care. Midodrine-octreotide, despite being cheaper per dose, had such a low response rate that the cost per successful outcome ballooned to nearly $5 million.26PubMed. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective
Outside the U.S., the economics look different. A separate analysis comparing terlipressin and norepinephrine from both public and private payer perspectives found relatively modest cost differences between the two, with terlipressin running slightly cheaper in both scenarios.27European Journal of Gastroenterology & Hepatology. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation A Thai cost-utility analysis similarly found terlipressin and norepinephrine in a similar range of cost-effectiveness, with norepinephrine becoming more competitive when administered outside the ICU.28PubMed Central. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome The takeaway is that drug acquisition cost alone does not determine value. Where the drug can be safely given, how often it works, and how much downstream care (dialysis, ICU days, transplant timing) it averts all factor in.